Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00109161 |
Recruitment Status :
Completed
First Posted : April 25, 2005
Last Update Posted : August 5, 2008
|
Sponsor:
PDL BioPharma, Inc.
Information provided by:
Facet Biotech
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Primary Completion Date : | No date given |
Study Completion Date : | October 2006 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):